Blood thinner dosing for children with Kawasaki aneurysm
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This study tests the best dose of a blood thinner called rivaroxaban for children with a giant coronary artery aneurysm after Kawasaki disease. The goal is to prevent dangerous blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a giant coronary artery aneurysm (a very wide blood vessel in the heart) after Kawasaki disease.
- Your child is at least 1 month old and weighs at least 5.7 pounds (2600 grams).
- Your child can take medicine by mouth or through a feeding tube.
- Your child does not have active bleeding or a high bleeding risk, severe kidney problems, or other conditions that would make blood thinners unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This study looks at how a blood thinner called rivaroxaban is used in babies under 2 who have had a blood clot. It aims to understand safety and patterns of use to help guide treatment for young children.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.